These days, one can almost be convinced of the reality of a truly efficient market, one that brings together buyers and sellers, matching excess capacity with need. The Internet promises to make this possible, by acting as the ultimate go-between. It is not only the purveyors of products that have realized the potential of the Internet's connectivity. Recently, several sites have gone up to facilitate the buying and selling of certain fungible but less tangible assets of R&D based companies. Yet2.com, Pharmalicensing.com,and PL-X.com all have web sites that seek to match buyers and sellers in technology transfer. PharmaUniverse.com hopes to create an efficient market for other pharmaceuticals assets like short-dated inventory or manufacturing capacity.
The Web, as E-Bay has definitively shown, can create relatively
efficient markets, bringing together diverse buyers and sellers.
Health care has seen a number of marketing and distribution plays,
like Ventro Corp. , Neoforma.com
Inc. , and MedAssets.com Inc.
Now companies are starting up to broker the often less obvious assets of the industry. The founders of drug delivery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.
A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.